Treatment of Sodium Retention in Liver Cirrhosis With Dexamethasone
NCT ID: NCT01311167
Last Updated: 2013-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
2 participants
INTERVENTIONAL
2011-02-28
2011-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites
NCT01716611
Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites
NCT00501722
Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites
NCT06812390
Mechanism and the Effect of Midodrine on Portal Pressures in Patients With Cirrhosis
NCT01331785
Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites
NCT02173288
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dexamethasone
Dexamethasone
Daily administration of 2 mg of dexamethasone for 4 days
Placebo
Placebo
Daily administration of 2 mg of placebo for 4 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexamethasone
Daily administration of 2 mg of dexamethasone for 4 days
Placebo
Daily administration of 2 mg of placebo for 4 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* hepatorenal syndrome type 1 or 2 (with a serum creatinin \>175 umol/l)
* age between 18 and 75
* no bacterial infection
* no cardiovascular or extrahepatic disease (end of life)
* no structural kidney disease
* no hepatocellular carcinoma
Exclusion Criteria
* treatment with corticosteroids (dexamethasone included)
* bacterial infection
* cardiovascular or extrahepatic disease (end of life)
* structural kidney disease (indicated by hematuria, proteinuria)
* hepatocellular carcinoma
* mental disability
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Geneva
OTHER
University of Lausanne Hospitals
OTHER
Insel Gruppe AG, University Hospital Bern
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Swiss National Foundation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Inselspital
Bern, Canton of Bern, Switzerland
University Hospital Geneva
Geneva, Canton of Geneva, Switzerland
University Hospital Lausanne
Lausanne, Canton of Vaud, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Dexa_Cirr_2011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.